Company intelligence / Profile preview
Metro International Biotech
Worcester, Massachusetts, United Statesmetrobiotech.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Metro International Biotech has robust preclinical data supporting the broad therapeutic potential of modulating NAD+. Its lead compound MIB‑626 has completed multiple Phase I trials demonstrating safety and tolerability. Ongoing Phase II studies are targeting COVID‑19, acute kidney injury, mild dementia, and other age-related conditions. The company also has a second clinical candidate in early-stage trials.
- Therapeutic areas
- NephrologyRare DiseasesOtherNeurologyInfectious Diseases
- Modalities
- Small molecules (NAD+ precursors/enhancers)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
U.S. Special Operations Command/SOCOM for studies on muscle energetics/human performance
Beyond the preview
Go deeper on Metro International Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metro International Biotech.